Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04472611 · ClinicalTrials.gov registry record · Phase 3
Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT04472611 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 250 participants.
The verdict
NCT04472611, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2
Interventions
- DRUG Standard of Care (SOC) and Colchicine+Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04472611
The ClinicalTrials.gov registry entry for NCT04472611 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care (SOC) and Colchicine+Rosuvastatin is the first listed.
NCT04472611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04472611 about?
NCT04472611 is a clinical study titled "Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial". This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2
What is the current status of trial NCT04472611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2020-10-30. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04472611?
The interventions under investigation include: Standard of Care (SOC) and Colchicine+Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT04472611?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.